Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Average PT from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $11.13.

A number of research firms recently weighed in on STRO. HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Sutro Biopharma in a research note on Monday, November 18th. Wells Fargo & Company decreased their price target on Sutro Biopharma from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research note on Wednesday, December 11th. JMP Securities restated a "market outperform" rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Wedbush reiterated an "outperform" rating and set a $8.00 target price on shares of Sutro Biopharma in a research report on Tuesday, December 10th.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of Sutro Biopharma in the fourth quarter worth $26,000. Gladius Capital Management LP acquired a new position in shares of Sutro Biopharma in the third quarter worth $28,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Sutro Biopharma in the fourth quarter worth $32,000. Vontobel Holding Ltd. raised its holdings in shares of Sutro Biopharma by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $46,000 after acquiring an additional 10,000 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Sutro Biopharma by 74.3% in the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock worth $50,000 after acquiring an additional 11,494 shares during the last quarter. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Stock Up 2.9 %

Shares of Sutro Biopharma stock traded up $0.05 during trading on Tuesday, reaching $1.79. The company's stock had a trading volume of 647,741 shares, compared to its average volume of 854,181. Sutro Biopharma has a 12-month low of $1.51 and a 12-month high of $6.13. The company has a market capitalization of $147.60 million, a P/E ratio of -1.11 and a beta of 1.15. The business has a 50 day moving average price of $1.94 and a 200-day moving average price of $3.06.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.